Translational control of SEPT9 isoforms is perturbed in disease
The Centre for Cancer Research and Cell Biology, School of Medicine and Dentistry, Queen's University Belfast, U-Floor, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, UK
* To whom correspondence should be addressed. Tel: +44 2890329241 ext. 2221; Fax: +44 2890263744; Email: seh.russell{at}qub.ac.uk
Received November 17, 2006; Revised December 18, 2006; Accepted January 19, 2007
A common feature of the mammalian septin gene family is complex genomic architecture with multiple alternate splice variants. Septin 9 has 18 distinct transcripts encoding 15 polypeptides, with two transcripts (SEPT9_v4 and v4*) encoding the same polypeptide. We have previously reported that the ratio of these distinct transcripts is altered in neoplasia, with the v4 transcript being the usual form in normal cells but v4* becoming predominant in tumours. This led us to ask what the functional differences between these two transcripts might be. The 5'-UTRs of v4 and v4* have distinct 5' ends encoded by exons 1ß (v4) and 1
and 2 (v4*) and a common 3' region and initiating ATG encoded within exon 3. Here we show that the two mRNAs are translated with different efficiencies and that cellular stress can alter this. A putative internal ribosome entry site can be identified in the common region of the v4 and v4* 5'-UTRs and translation is modulated by an upstream open-reading frame in the unique region of the v4 5'-UTR. Germline mutations in hereditary neuralgic amyotrophy (HNA) map to the region which is common to the two UTRs. These mutations dramatically enhance the translational efficiency of the v4 5'-UTR, leading to elevated SEPT9_v4 protein under hypoxic conditions. Our data provide a mechanistic insight into how the HNA mutations can alter the fine control of SEPT9_v4 protein and its regulation under physiologically relevant conditions and are consistent with the episodic and stress-induced nature of the clinical features of HNA.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. C. Hannibal, E. K. Ruzzo, L. R. Miller, B. Betz, J. G. Buchan, D. M. Knutzen, K. Barnett, M. L. Landsverk, A. Brice, E. LeGuern, et al. SEPT9 gene sequencing analysis reveals recurrent mutations in hereditary neuralgic amyotrophy Neurology, May 19, 2009; 72(20): 1755 - 1759. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Landsverk, E. K. Ruzzo, H. C. Mefford, K. Buysse, J. G. Buchan, E. E. Eichler, E. M. Petty, E. A. Peterson, D. M. Knutzen, K. Barnett, et al. Duplication within the SEPT9 gene associated with a founder effect in North American families with hereditary neuralgic amyotrophy Hum. Mol. Genet., April 1, 2009; 18(7): 1200 - 1208. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Klein, Y. Wu, J. M. Cunningham, A. J. Windebank, P. J. B. Dyck, S. M. Friedenberg, D. M. Klein, and P. J. Dyck SEPT9 Mutations and a Conserved 17q25 Sequence in Sporadic and Hereditary Brachial Plexus Neuropathy Arch Neurol, February 1, 2009; 66(2): 238 - 243. [Abstract] [Full Text] [PDF] |
||||


